| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Christopher McElvany | President and CEO, Director | $3,540,794 | 13 Feb 2023 | ||
| Livio Susin | Director | $323,542 | 13 Feb 2023 | ||
| Assad J. Kazeminy | Chief Scientific Officer | $204,000 | 13 Feb 2023 | ||
| Scott M. Reeves | Director | $66,667 | 08 Feb 2023 | ||
| Brittany Kaiser | Director | 08 Feb 2023 | |||
| CHARLES B. NEMEROFF | Director | 08 Feb 2023 | |||
| Brian Zasitko | Chief Financial Officer | 08 Feb 2023 | |||
| RICHARD D. NANULA | Executive Chairman, Director | 08 Feb 2023 | |||
| PAUL ABRAMOWITZ | Director | 08 Feb 2023 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Christopher McElvany | Common Shares | Other | 118,403 | 118,403 | 13 Feb 2023 | By Supercritical Labs, LLC | ||||
| Christopher McElvany | Common Shares | Conversion of derivative security | 366,187 | 366,187 | 13 Feb 2023 | By Downwind Investments, LLC | ||||
| Christopher McElvany | 8% Convertible Promissory Note | Conversion of derivative security | -100% | -500,000 | 0 | 13 Feb 2023 | By: Downwind Investments, LLC | |||
| Livio Susin | Common Shares | Other | 7.42% | 9,309 | 134,809 | 13 Feb 2023 | Direct | |||
| Assad J. Kazeminy | Common Shares | Other | 85,000 | 85,000 | 13 Feb 2023 | ALK Biopharmaceutical LLC |